Dr. Maccecchini was elected to Lantern's Board of Directors in June of 2022. She is the Founder, President, CEO and Executive Board Member of Annovis Bio. Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Presently, her drugs are being tested in phase 2 and phase 3 clinical studies for Alzheimer’s and Parkinson’s disease. She was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group. She was the Founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that sold in 2001 to Transgenomic, the General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and was also the Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini did one postdoc at Caltech and one at The Roche Institute of Immunology, and her PhD in Biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.